Registration onsite from 10:00 am
| Program XIV International Symposium on Vasoactive Peptides | |
| FRIDAY – 11/17/2023 | |
| 2:00 – 2:15 p.m. | OPENING SESSION Robson Santos – Symposium Chair Raphael Escorsim Szawka – Coordinator of the Graduate Program in Biological Sciences: Physiology and Pharmacology – UFMG |
| 2:15 – 3:30 p.m. | SESSION I Chair: Maria José Campagnole-Santos; Michael Bader |
| 2:15 – 2:45 p.m. | The vasopeptidase world – from the RAS to Long Covid. Anthony Turner, UK |
| 2:45 – 3:15 p.m. | Targeting strategies for ACE2 ubiquitination in diseases. Eric Lazartigues, USA. |
| 3:15 – 3:30 p.m. | Oral presentation I: Angiotensin-(1-7) Improve Early Host Immune Responses, And Exerts Pro-Resolving Effects In A Model Of Severe Dengue Infection. Viviane Lima Batista, Federal University of Minas Gerais, Brazil |
| 3:30 – 3:45 p.m. | COFFEE BREAK |
| 3:45 – 5:45 p.m. | SESSION II Chair: Maria Luiza Chaves; Ulrike Steckelings |
| 3:45 – 4:15 p.m. | Single cell analysis of the Renin Angiotensin System in the paraventricular nucleus of hypothalamic during hypertension and obesity. Yumei Feng Earley, USA. |
| 4:15 – 4:45 p.m. | Anti-inflammatory response of Mas receptor: dialogue with other receptors. Mariela Gironacci, Argentina. |
| 4:45 – 5:15 p.m. | Inhibitors of SGLT-2 cotransporters: beyond Glycemic Control. Maria Cláudia Irigoyen, Brazil. |
| 5:15 – 5:45 p.m. | Is there an endogenous AT2-receptor agonist? Latest data on angiotensin-(1-5). Ulrike Steckelings, Denmark. |
| 6:00 – 8:00 p.m. | POSTER SESSION |
| SATURDAY– 11/18/2023 | |
| 9:00 – 10:30 a.m. | SESSION III Chair: Edilamar Oliveira; Patricia Gallagher |
| 9:00 – 9:30 a.m. | Angiotensin-(1-7): a novel pharmacological tool against vascular ageing? Concepción Peiró, Spain. |
| 9:30 – 10:00 a.m. | Developmental origins of cardiovascular diseases after preterm birth: from bench to bedside and back. Anne Monique Nuyt, Canada. |
| 10:00 – 10:30 a.m. | Metabolically stable apelin analogs in hyponatremia and heart failure after myocardial infarction. Catherine Llorens-Cortes, France. |
| 10:30 – 10:45 a.m. | COFFEE BREAK |
| 10:45- 12:45 p.m. | SESSION IV Chair: Carlos Castro; Jan Danser. |
| 10:45 – 11:15 a.m. | Interplay between Ang-(1-7) and endothelin – a novel vasoprotective mechanism. Rhian Touyz, Canada. |
| 11:15 – 11:45 a.m. | Apelin receptor axis – a novel therapeutic pathway in preeclampsia. Liliya Yamaleyeva, USA. |
| 11:45 – 12:15 p.m. | Dysfunction of the Renin-Angiotensin-Aldosterone System in Septic Shock. Mark Chappell, USA. |
| 12:15 – 12:30 p.m. | Oral presentation II: Elastase-2 Expression In Human Abdominal Aortic Aneurysms: A Novel Finding In Disease Pathogenesis. Vinicius Flora Dugaich, Ribeirão Preto Medical School, University of São Paulo, Brazil |
| 12:30 – 12:45 p.m. | Oral presentation III : Angiotensin-(1-7), A Potential Adjuvant To Doxorubicin Cancer Therapy, Reduces Nephrotoxicity By Decreasing Oxidative Stress And Fibrosis. Ana Clara Melo, Wake Forest University, USA |
| 12:45 – 2:00 p.m. | LUNCH BREAK |
| 2:00 – 4:00 p.m. | SESSION V Chair: Maria de Fátima Leite; Patricia Chakur Brum |
| 2:00 – 2:30 p.m. | Hypertension treatment by immunotherapy. The new frontier. Carlos Ferrario, USA. |
| 2:30 – 3:00 p.m. | The first retro-enantiomers for the RAS. María Paz Ocaranza, Chile. |
| 3:00 – 3:30 p.m. | Novel antihypertensives, and in particular angiotensinogen siRNA. Jan Danser, USA. |
| 3:30 – 4:00 p.m. | Angiotensin-(1-7): A Prospective Cancer Therapeutic. Patricia Gallagher, USA. |
| 4:00 – 4:15 p.m. | COFFEE BREAK |
| 4:15 – 6:15 p.m. | SESSION VI Chair: Eric Lazartigues; Lucíola Barcelos |
| 4:15 – 4:45 p.m. | Angiotensin-(1-7) and the Vasculogenic Function of CD34+ cells in Diabetes: Role of Telomerase Reverse Transcriptase. Yagna Jarajapu, USA. |
| 4:45 – 5:15 p.m. | RAS manipulation in the critically ill patient. Filippo Annoni, Belgium. |
| 5:15 – 5:45 p.m. | Angiotensin peptides in the uterus: Paracrine actions beyond circulation. Fernando Reis, Brazil. |
| 5:45 – 6:00 p.m. | Oral presentation IV: Sympathetic Neural Overactivity, Endothelial Dysfunction, Aortic Stiffening, And Diminished Exercise Capacity In Breast Cancer Survivors Treated With Doxorubicin And Trastuzumab-Based Chemotherapy. João Eduardo Izaias, D’Or Institute for Research and Education, Brazil |
| 6:00 – 6:15 p.m. | Oral presentation V: Reduced Renal Hepcidin Clearance Contributes To Anemia In Angiotensinogen Deficient Mice. André F. Rodrigues, Max Delbrück Center, Germany |
| 6:15 – 6:45 p.m. | MrgD knock-out mice: new molecular and functional findings. Thiago Verano Braga, Brazil. |
| SUNDAY– 11/19/2023 | |
| 9:00 – 10:00 a.m. | SESSION VII Chair: Kátia De Angelis; Anna Monique Nuyt. |
| 9:00 – 9:30 a.m. | The role of Angiotensin-(1-7)/MasR axis in preclinical models of infectious diseases. Lirlândia Sousa, Brazil. |
| 9:30 – 10:00 a.m. | Cellular and molecular mechanisms in the development of heart failure with preserved ejection fraction. Sergio Lavandero, Chile. |
| 10:00 – 10:15 a.m. | COFFEE BREAK |
| 10:15 – 12:00 p.m. | SESSION VIII Chair: Dulce Casarini; Rike Kemplin |
| 10:15 – 10:30 a.m. | Oral presentation VI: Assessment Of Gene Expression Of MAS And MRGD Receptors In The Nasal Epithelium Of Eutrophic And Obese Individuals Infected With SARS-Cov-2. Jonathan Lopes Moreira, Federal University of the Jequitinhonha and Mucuri Valleys, Brazil |
| 10:30 – 10:45 a.m. | Oral presentation VII: The new MAS receptor agonist, CGEN-856S, activates nitric oxide signaling in cardiomyocytes. Kiany Miranda, Federal University of Minas Gerais |
| 10:45 – 11:15 a.m. | Functional autoantibodies against the angiotensin II AT1- and angiotensin 1-7 MAS receptor in SARS-CoV-2 infected patients with long-COVID symptoms. Gerd Wallukat, Germany. |
| 11:15 – 11:45 a.m. | Carboxypeptidases as potential drug targets: News on CPM and ACE2. Michael Bader, Germany. |
| 12:00 p.m. | Awards Session and Closing Ceremony |
XIV International Symposium on Vasoactive Peptides 